Get the Stockscreener App
2.65
2.71%
0.07
After Hours:
2.57
-0.08
-3.02%
AIM ImmunoTech Inc stock is traded at $2.65, with a volume of 42,371.
It is up +2.71% in the last 24 hours and up +1.92% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$2.58
Open:
$2.55
24h Volume:
42,371
Relative Volume:
0.21
Market Cap:
$7.18M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-4.4167
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
+0.76%
1M Performance:
+1.92%
6M Performance:
+2,692%
1Y Performance:
+923.17%
1-Day Range:
$2.50
$2.66
1-Week Range:
$2.48
$2.72
52-Week Range:
$0.0633
$20.35
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
2.65 | 6.99M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
AIM ImmunoTech Inc Stock (AIM) Latest News
Can AIM ImmunoTech Inc. (HXB) stock sustain breakout momentumRate Hike & Fast Gaining Stock Reports - newser.com
How AIM ImmunoTech Inc. stock stacks up against competitorsJuly 2025 PreEarnings & Real-Time Volume Trigger Notifications - newser.com
Why AIM ImmunoTech Inc. stock remains top ratedJuly 2025 Levels & Reliable Entry Point Alerts - newser.com
All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy - sharewise.com
Will AIM ImmunoTech Inc. stock keep raising dividendsMarket Volume Report & Advanced Swing Trade Entry Plans - newser.com
What drives AIM ImmunoTech Inc HXB stock priceMomentum Trading Signals & Small Capital Growth Tips - earlytimes.in
Financial Comparison: AIM ImmunoTech (NYSEAMERICAN:AIM) versus Osiris Therapeutics (OTCMKTS:OSIR) - Defense World
Can AIM ImmunoTech Inc. (HXB) stock hit consensus price targetsJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - newser.com
How AIM ImmunoTech Inc. (HXB) stock performs in volatility spikesMarket Activity Summary & Safe Entry Point Alerts - newser.com
How AIM ImmunoTech Inc. (HXB) stock compares with top peersTrend Reversal & Entry and Exit Point Strategies - newser.com
Will AIM ImmunoTech Inc. (HXB) stock benefit from Fed rate cutsQuarterly Profit Review & Low Drawdown Momentum Trade Ideas - newser.com
AIM: Ascendiant Capital Updates Price Target for AIM ImmunoTech - GuruFocus
AIM ImmunoTech Secures Japan Patent for Novel Cancer Product - NAVLIN DAILY
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):